Tom Castles

Asthma is the most common chronic disease of childhood. Cellphones might help improve its management.

Results may ease concerns for many physicians and patients who live in colder climates.

Demystifying the oral food challenge starts with understanding its risks and benefits.

Study co-author Nicola Alexander Hanania, MD, explains what the new data means for practicing pulmonologists and allergists.

Busse explains the importance of having an additional treatment option and covers best practices for prescribing.

In 2017, roughly 5% of newborns had a peanut allergy. That’s a stark increase from the roughly 1% that characterized previous decades, according to researchers.

Researchers uncover the first report of cannabis allergy, suggesting that exposure to secondhand marijuana smoke may contribute to difficult-to-control asthma.

FF/VI met primary and secondary endpoints in increasing the mean proportion of days covered and time to index treatment discontinuation.

Researchers sought to balance the cost of autoinjectors with their lifesaving potential, and then boil the results down to an agreeable number. Here’s where they landed.

An updated epidemiological review paints a concerning picture of pediatric cow’s milk allergy in the US.

On the bright side: In-hospital education shown to be effective in helping bridge the gap.

Sterilizing or hand washing pacifiers doesn’t have the same allergy-suppressing benefits as sucking on them, according to new research.

In a real-world setting, omalizumab improved UAS scores, DLQI scores, response scores, and saw a similar or better safety profile.

The therapy saw similar safety and efficacy profiles across the BORA, SIROCCO and CALIMA studies for the treatment of asthma.

Efficacy was superior to placebo regardless of patient BMI, supporting adequacy of recommended dosing regimens for overweight and obese patients.

The new formulation, known as Xolair PFS, will be available in the US by the end of the year.

Times are tough. Medicine needs a hero.